When TAVI was first introduced, the anesthetic approach most usually chosen was general anesthesia (GA) with endotracheal intubation. 10−14 Recently, some single-center investigations have demonstrated the possibility of transfemoral-TAVI Background-Transcatheter aortic valve implantation (TAVI) performed under local anesthesia (LA) is becoming increasingly common. We aimed to compare the clinical outcomes in patients who underwent transfemoral-TAVI under general anesthesia (GA) and LA.
T ranscatheter aortic valve implantation (TAVI) has emerged as a promising alternative to conventional surgical aortic valve replacement for patients with severe, symptomatic aortic stenosis who would otherwise be left untreated because of the high perceived risk of operative mortality. 1 Since the first-in-man procedure in 2002, 2 several improvements have been achieved in TAVI device technologies and procedural management, leading to an increase in the success rates of the procedure. 3−9 TAVI is currently a viable treatment option for inoperable patients or patients at high risk for conventional surgical aortic valve replacement-related complications; however, several clinical problems associated with the management of such high-risk patients remain, and anesthetic management during TAVI is controversial.
(TF-TAVI) under local anesthesia (LA), drawing on their increased experience of the technique and improvements in the devices used. 15−19 However, there is still a lack of largescale multicenter data reflecting real-world clinical experience of the anesthetic approach during TAVI. Recently, the results of studies based on the French Aortic National CoreValve and Edwards 2 (FRANCE 2) Registry have been reported. 20 The current study, a subanalysis of the FRANCE 2 Registry, aimed to compare the clinical outcomes of patients who underwent TF-TAVI under GA and LA.
Methods

Patient Selection
In January 2010, a national TAVI coordination and monitoring program were established in France to analyze patient characteristics and clinical outcomes in 33 medical centers in France and 1 center in Monaco that had the capability of performing TAVI using one of the following surgical approaches: TF, transapical, subclavian, or other techniques, such as the direct transaortic or carotid routes. Each multidisciplinary team performing the procedure consisted of an interventional cardiologist, cardiothoracic surgeon, cardiologist, echocardiographer, anesthetist, imaging specialist, and geriatrician. These teams identified symptomatic patients who required TAVI for severe aortic stenosis and who were ineligible for surgical aortic valve replacement owing to comorbidities that placed them at high risk. All eligible patients meeting these criteria were prospectively included. In all centers, the team determined TAVI eligibility based on a systematic clinical, angiographic, multislice computed tomographic, and echocardiographic assessment. In total, 3195 patients underwent TAVI in 34 hospitals between January 2010 and October 2011. In 2361 of these patients, the TF approach was used (74% of the total population of the FRANCE 2 Registry). Details of the anesthetic method were unavailable for 35 patients, who were excluded from the analysis. Data from the remaining 2326 patients were prospectively analyzed for differences related to the anesthetic method used: GA (n=1377) or LA (n=949), where LA indicates both LA exclusively and LA with venous sedation, but without mechanical ventilation. All patients provided written informed consent before the procedure and assented to anonymous processing of their data. The registry was approved by the Institutional Review Board of the French Ministry of Health.
Transcatheter Aortic Valve Implantation Procedure
The technical aspects of the TAVI procedure have been previously reported in detail. [2] [3] [4] [5] Two TAVI systems are commercially available: a self-expandable prosthesis, the Medtronic CoreValve Revalving System (CoreValve; Medtronic, Minneapolis, MN); and a balloon-expandable prosthesis, the Edwards SAPIEN or SAPIEN XT (Edwards valve; Edwards Lifesciences, Irvine, CA). The prosthesis size was determined from preprocedural transesophageal echocardiography (TEE) and multislice computed tomographic findings based on the current commercial recommendation. There were no prespecified recommendations with respect to the use of a TF, transaortic, or subclavian approach. The choice between GA and LA was left to the discretion of the local team. TAVI procedures were performed in an operating room, a hybrid room, or a cardiac catheterization laboratory, depending on the facilities available in each center.
Data Management
Mortality was adjudicated by an independent clinical events committee. All adverse events were assessed according to the Valve Academic Research Consortium (VARC) criteria. 21 Device success and other procedural complications during TAVI were assessed based on the VARC classifications. The combined safety end point was defined to include the following: all-cause mortality, major stroke, life-threatening bleeding, acute kidney injury stage 3, periprocedural myocardial infarction, major vascular complication, and repeat procedure for valve-related dysfunction (surgical or interventional therapy). Postprocedural aortic regurgitation (AR) and mitral regurgitation were assessed by echocardiography. Data were recorded on a standardized electronic case report form and sent to a central Internet database (AXONAL, Nanterre, France).
Statistical Analysis
All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) software (version 19; SPSS Inc, Chicago, IL). Continuous variables were expressed as mean±SD, whereas categorical data were expressed as a percentage of the total. Two groups of patients were defined for the purpose of analysis: GA and LA. Between-group comparisons were performed using Pearson bivariate test and the χ 2 test for categorical covariates, and 1-way analysis of variance (ANOVA) for continuous covariates. In addition
WHAT IS KNOWN
• With evolution of devices and increasing experience, there is a trend at many centers to perform transfemoral transcatheter aortic valve implantation under local rather than general anesthesia.
• Data from small studies demonstrated the feasibility of transfemoral transcatheter aortic valve implantation under local anesthesia, but large-scale studies evaluating the relationship between anesthetic approach and outcomes have not been reported.
WHAT THE STUDY ADDS
• Among patients entered into the national registry of transcatheter aortic valve implantation in France, clinical outcomes other than postprocedural aortic regurgitation did not differ between patients treated under general and local anesthesia.
• A higher incidence of postprocedural aortic regurgitation in the local anesthesia group was attenuated after analysis with propensity matching that included the use of transesophageal echocardiography, which was significantly more common in the general anesthesia cohort.
• The propensity-matched analyses also demonstrated no significant difference in survival or other adverse outcomes between the 2 anesthetic management approaches. to the P value in the baseline and the procedural characteristics, we presented standardized differences (Cohen d) or Pearson r to show the effect size between the 2 groups. Propensity score matching was conducted using the nearest neighbor matching method within a caliper of 0.01. All patients treated under GA were matched in a 1:1 match. Propensity scores were calculated for each patient using multivariate logistic regression based on the all clinically important covariates: age, sex, body mass index, New York Heart Association 3 and 4, peripheral artery disease, previous myocardial infarction, previous stroke, previous cardiac surgery, diabetes mellitus, hypertension, dyslipidemia, chronic obstructive pulmonary disease, logistic European system for cardiac operative risk evaluation, ejection fraction, mean pressure gradient, pre-AR≥mild, pre-mitral regurgitation≥mild, TEE use, All CoreValve. The discrimination and calibration abilities of the propensity score were adequately assessed by means of C statistics (0.83) and the Hosmer-Lemeshow test (P=0.65). The Kaplan-Meier method was used to estimate the cumulative mortality rates of the groups. Mortality rates at 30 days and 1 year were also calculated. These mortality rates in each group were compared using the log-rank test, which was also applied to compare 30-day and 1-year mortality rates in the 2 anesthesia groups. Subgroup analyses of 30-day and 1-year mortalities were performed in the 2 groups (eg, sex, valve type, TEE use, and experience). All patients were compared with the adjustment by quintile of propensity score. Hazard ratio and 95% confidence intervals are presented for the cumulative 30-day and 1-year mortalities in patients treated under LA and GA. In addition, hazard risk was also compared between the matched sample models. All statistical tests were 2-sided, and a P value <0.05 was considered significant.
Results
Baseline Patient and Procedural Characteristics
GA was the predominant anesthetic approach used in the first month of the study (GA, 86% versus LA, 14%) but the balance gradually shifted toward LA by the final month (GA, 41% versus LA, 59%; Figure 1 ). The baseline demographic, clinical, and echocardiographic characteristics of the study population are summarized in Table 1 . The mean patient age was 83.1±7.2 years, and 53% of patients were women. There were numerous differences between the 2 anesthesia groups about sex and prevalence of other baseline patient characteristics, including echocardiographic data (Table 1) . Procedural characteristics, VARC defined, and other procedural complications Postprocedural AR≥mild was significantly less common in the GA group than in the LA group (15.0% versus 19.1%; P=0.015). No significant differences between the 2 groups were observed in the incidence of VARC-defined complications (myocardial infarction, stroke, and vascular and bleeding complications) or other procedural complications. After matching based on the propensity analysis, baseline patient characteristics were similar in the 2 groups (Table 3) . Procedure-related clinical outcomes were also compared for the 2 matched models (Table 4 ). No significant differences between the GA and LA groups were observed in the incidence of VARC-defined complications; postprocedural AR≥mild also showed no significant difference between the 2 groups (12.7% versus 16.2%; P=0. 19 ). were also compared between the GA and LA groups after propensity matching ( Figure 3 ). The rates of 30-day survival showed no significant differences between the groups (GA, 91.4% versus LA, 89.3%; P=0.27), and the results of 1-year survival were not changed (GA, 75.7% versus LA, 77.7%; P=0.44). A further analysis of cumulative 30-day and 1-year mortalities was performed for the 2 anesthesia groups overall and for subgroups according to sex, valve type, TEE use, and era ( Figure 4 ). No significant difference was observed between the GA and LA groups in either 30-day or 1-year mortality.
Cumulative Survival Rate
Discussion
The current results from the national multicenter FRANCE 2 registry describe the real-world experience from 2326 patients undergoing TF-TAVI. At present, in France, ≥50% of TF-TAVI procedures are performed under LA, with or without sedation. The present study demonstrated similar clinical outcomes for GA and LA with regard to procedure success, incidence of VARC-defined complications, 30-day and 1-year survival rates, and the exception being the incidence of postprocedural AR. The propensity-matched model also demonstrated no significant differences about mortality and the 
Anesthetic Method Trends
We identified a trend in the FRANCE 2 registry in which the use of GA gradually shifted to LA. This represents the French experience, which is different from that of North America, where GA is the predominant method and LA is used in only 5% of TAVI procedures. 22 The present study also demonstrated significant differences between GA and LA in the room where the procedure was performed. The choice of anesthetic method could be associated with the available facilities. This equipment setup is only available in a few centers in France, and most procedures are currently performed in a cardiac catheterization laboratory. 23 Recent developments in vascular repair techniques may favor the use of LA, even with the subclavian approach. 24−26
Safety of TF-TAVI Under LA
In the present study, there was a tendency for postprocedural AR≥mild to be more common in the LA group than in the GA group in the total patient population. There was a significant difference in TEE use during TAVI between the GA and LA groups (GA, 76.3% versus LA, 16.9%; P<0.001). After matching on the propensity analysis, post-AR≥mild did not show any significant difference (GA, 13% versus LA, 16%; P=0. 19 ) although the incidence was still higher in the LA group than in the GA. This result may support the importance of TEE support during TAVI for reducing the incidence of postprocedural AR. In general, TEE monitoring, in conjunction with fluoroscopy and contrast angiography, provides useful information during TAVI. 27−28 If TEE evaluation is required during TAVI under LA for complications, such as unexplained hemodynamic instability, or to distinguish between transvalvular and perivalvular AR, it is essential that the TEE findings be assessed immediately, even if this involves changing the anesthetic method from LA to GA. LA failure that required conversion to GA during the procedure occurred in some cases. A previous report revealed that the incidence of LA failure during TAVI was 17% of a total of 100 patients. 17 Another recent report showed a 4.6% LA failure rate in 174 TF-TAVI cases. 18 In our study, procedural failure occurred in 119 cases (5.1%) overall, 57 cases (6.0%) in the LA group, and 62 cases (4.5%) in the GA group, and there was no significant difference between the LA and GA groups (P=0.13).
LA failure was strongly associated with procedural complications and adverse outcomes. 18 It is acceptable to change the strategy when serious problems are encountered, to manage any complication in the best possible manner. It might be different if the use of LA itself was associated with a higher rate of complications.
Who Is a Good Candidate for LA?
The present study revealed that LA was not inferior when compared with GA; moreover, there might be cases in which LA is preferable. There are both advantages and disadvantages to each anesthetic method. 23 GA ensures patient immobility and control of respiration, avoids ventilator artifacts that can interfere with prosthesis placement, and facilitates the management of any procedural complications. However, GA requires endotracheal intubation, and mechanical ventilation can be associated with several complications, including hemodynamic instability and respiratory compromise, which may be poorly tolerated in high-risk or elderly patients who are ineligible for surgical aortic valve replacement. Although we could not compare hospital costs between the GA and LA groups in the present study, a previous study demonstrated that the labor costs associated with TAVI performed under LA were significantly lower relative to those of GA. 16 By keeping patients awake under LA, neurological and pain monitoring during TAVI enables the rapid detection of stroke and vascular complications. The TAVI populations were mainly comprised elderly patients; thus, the less invasive LA method was thought to be more comfortable for these patients. Apart from the differences in anesthesia, it should be noted that TAVI procedures without TEE guidance do not allow for the precise evaluation of paravalvular AR. If the operators did not use TEE during TAVI, the assessment of paravalvular leak after aortic valve implantation had to be made on the basis of multimodality approaches, including aortic root angiography, transthoracic echocardiography, and hemodynamic methods (eg, AR index).
Limitations
The following limitations apply to the current study. Although the data about the numbers of procedures and survival outcomes are extremely robust, those concerning morbidity and complications are likely to be less so because they are selfreported and not independently adjudicated, owing to the lack of central echocardiography and neurology core laboratories. In addition, the FRANCE 2 Registry is a nonrandomized clinical investigation. Therefore, differences in clinical backgrounds may exist between the 2 groups included in this study. It was also difficult to achieve complete clinical follow-up because this registry did not include patients from all French TAVI centers. The short follow-up period of a median 137 days was insufficient for analyzing midterm mortality. Therefore, the results about similar cumulative 1-year mortality rates in the 2 groups should not be overstated. The importance of TEE during TAVI is in precisely evaluating the degree or type of AR. The TEE findings may influence operators to opt for more frequent postdilatation immediately after prosthesis implantation and may contribute to the lower incidence of postprocedural AR. However, information about after dilation was not included in the data analyzed in this study. The percentage of TEE use under TAVI was significantly differed between the patients treated under GA and LA (76.3% versus 16.9%). As a result, the majority of GA sample was lost after propensity matching, and matched GA sample was not reaching ≥50% of the entire GA cohort. Although we did make an effort to adjust and improve the statistical approach, this difference reduced the generalizability of the propensity-matched results.
Conclusions
TF-TAVI under LA has similar clinical outcomes when compared with that under GA with regard to 30-day mortality, procedural success, and the incidence of VARC-defined complications. However, the higher incidence of postprocedural AR in the LA group warrants further investigation. This result may be explained by the lower usage of TEE guidance during TAVI under LA. Although less invasive LA management in procedures performed by a heart team might be a reasonable therapeutic consideration in TF-TAVI, efforts to reduce procedural complications should be continued.
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